Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2443364,Total radioactivity,"Total radioactivity declined from a mean of 408 pg equiv/ml in three phases, with half-lives of 24 min, 1.7 h and 5.0 h, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[equiv·pg] / [ml],408,12081,DB01240,Epoprostenol
,2443364,half-lives,"Total radioactivity declined from a mean of 408 pg equiv/ml in three phases, with half-lives of 24 min, 1.7 h and 5.0 h, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),min,24,12082,DB01240,Epoprostenol
,2443364,half-lives,"Total radioactivity declined from a mean of 408 pg equiv/ml in three phases, with half-lives of 24 min, 1.7 h and 5.0 h, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),h,1.7,12083,DB01240,Epoprostenol
,2443364,half-lives,"Total radioactivity declined from a mean of 408 pg equiv/ml in three phases, with half-lives of 24 min, 1.7 h and 5.0 h, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),h,5.0,12084,DB01240,Epoprostenol
,2443364,peak,A steady-state of unchanged iloprost was reached rapidly with a peak of 81 pg/ml.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[pg] / [ml],81,12085,DB01240,Epoprostenol
,2443364,half-lives,Plasma levels declined biphasically with half-lives of 6 min and 31 min.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),min,6,12086,DB01240,Epoprostenol
,2443364,half-lives,Plasma levels declined biphasically with half-lives of 6 min and 31 min.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),min,31,12087,DB01240,Epoprostenol
,2443364,Total clearance,Total clearance was 24 ml X min-1 X kg-1.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[ml] / [kg·min],24,12088,DB01240,Epoprostenol
,2443364,Maximum concentrations,"Maximum concentrations of labeled substances after oral administration were 307 and 1,051 pg equiv/ml after 29 and 39 min, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[equiv·pg] / [ml],307,12089,DB01240,Epoprostenol
,2443364,Maximum concentrations,"Maximum concentrations of labeled substances after oral administration were 307 and 1,051 pg equiv/ml after 29 and 39 min, respectively.",Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[equiv·pg] / [ml],"1,051",12090,DB01240,Epoprostenol
,2443364,peak,The peak of unchanged iloprost (116 pg/ml) was observed 7.5 min after an oral dose of 0.48 microgram/kg.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),[pg] / [ml],116,12091,DB01240,Epoprostenol
,2443364,Bioavailability,Bioavailability was 16%.,Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2443364/),%,16,12092,DB01240,Epoprostenol
,22515646,t(1/2),"After infusion of the two formulations of epoprostenol, the t(1/2) values expressed as geometric mean (95% confidence interval) were 0.25 h (0.14, 0.46) and 0.22 h (0.13, 0.38) for 6-keto-prostacyclin F(1α) , and 0.32 h (0.22, 0.45) and 0.34 h (0.26, 0.46) for 6,15-diketo-13,14-dihydro-prostacyclin F(1α) .",Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515646/),h,0.25,12169,DB01240,Epoprostenol
,22515646,t(1/2),"After infusion of the two formulations of epoprostenol, the t(1/2) values expressed as geometric mean (95% confidence interval) were 0.25 h (0.14, 0.46) and 0.22 h (0.13, 0.38) for 6-keto-prostacyclin F(1α) , and 0.32 h (0.22, 0.45) and 0.34 h (0.26, 0.46) for 6,15-diketo-13,14-dihydro-prostacyclin F(1α) .",Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515646/),h,0.22,12170,DB01240,Epoprostenol
,22515646,t(1/2),"After infusion of the two formulations of epoprostenol, the t(1/2) values expressed as geometric mean (95% confidence interval) were 0.25 h (0.14, 0.46) and 0.22 h (0.13, 0.38) for 6-keto-prostacyclin F(1α) , and 0.32 h (0.22, 0.45) and 0.34 h (0.26, 0.46) for 6,15-diketo-13,14-dihydro-prostacyclin F(1α) .",Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515646/),h,0.32,12171,DB01240,Epoprostenol
,22515646,t(1/2),"After infusion of the two formulations of epoprostenol, the t(1/2) values expressed as geometric mean (95% confidence interval) were 0.25 h (0.14, 0.46) and 0.22 h (0.13, 0.38) for 6-keto-prostacyclin F(1α) , and 0.32 h (0.22, 0.45) and 0.34 h (0.26, 0.46) for 6,15-diketo-13,14-dihydro-prostacyclin F(1α) .",Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515646/),h,0.34,12172,DB01240,Epoprostenol
,2423342,steady-state plasma levels,"Following i.v. infusion, the steady-state plasma levels of iloprost were strictly dose-dependent (46 +/- 8 pg/ml and 135 +/- 24 pg/ml).",Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),[pg] / [ml],46,12353,DB01240,Epoprostenol
,2423342,steady-state plasma levels,"Following i.v. infusion, the steady-state plasma levels of iloprost were strictly dose-dependent (46 +/- 8 pg/ml and 135 +/- 24 pg/ml).",Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),[pg] / [ml],135,12354,DB01240,Epoprostenol
,2423342,half-lives,The disposition was biphasic with half-lives of 3-4 min and 0.5 h.,Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),min,3-4,12355,DB01240,Epoprostenol
,2423342,half-lives,The disposition was biphasic with half-lives of 3-4 min and 0.5 h.,Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),h,0.5,12356,DB01240,Epoprostenol
,2423342,maximum plasma level,"After oral administration, absorption of the drug was extremely rapid, the maximum plasma level of 251 +/- 32 pg/ml being achieved after 10 +/- 6 min.",Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),[pg] / [ml],251,12357,DB01240,Epoprostenol
,2423342,bioavailability,The bioavailability was 16 +/- 4%.,Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423342/),%,16,12358,DB01240,Epoprostenol
,6208562,half-life,After a rapid distribution phase the plasma level of radioactive substances declined with a half-life of 44 min.,"Pharmacokinetics and pharmacodynamics of the stable prostacyclin analogue, ZK 36 374, in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6208562/),min,44,26380,DB01240,Epoprostenol
,6208562,half-lives,The disposition of the unchanged drug was biphasic with half-lives of 7 min and 36 min.,"Pharmacokinetics and pharmacodynamics of the stable prostacyclin analogue, ZK 36 374, in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6208562/),min,7,26381,DB01240,Epoprostenol
,6208562,half-lives,The disposition of the unchanged drug was biphasic with half-lives of 7 min and 36 min.,"Pharmacokinetics and pharmacodynamics of the stable prostacyclin analogue, ZK 36 374, in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6208562/),min,36,26382,DB01240,Epoprostenol
,26220250,flow rate,"Relative to a design target of 0.042 mL/hr, the average flow rate of 23 PatchPumps operating for 48 continuous hours was 0.043 ± 0.007 mL/hr as tested in vitro.","In Vitro and In Vivo Performance of a Pre-Filled, Electrochemically-Actuated Infusion System. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26220250/),[ml] / [h],0.043,40776,DB01240,Epoprostenol
,26220250,Css,"PK results with an infusion rate of 0.045 mL/hr of treprostinil resulted in mean Css of 297 pg/mL and T1/2 of 4.44 h, comparable to prior studies using conventional infusion pumps.","In Vitro and In Vivo Performance of a Pre-Filled, Electrochemically-Actuated Infusion System. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26220250/),[pg] / [ml],297,40777,DB01240,Epoprostenol
,26220250,T1/2,"PK results with an infusion rate of 0.045 mL/hr of treprostinil resulted in mean Css of 297 pg/mL and T1/2 of 4.44 h, comparable to prior studies using conventional infusion pumps.","In Vitro and In Vivo Performance of a Pre-Filled, Electrochemically-Actuated Infusion System. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26220250/),h,4.44,40778,DB01240,Epoprostenol
,27885399,total body clearance,A geometric mean total body clearance (95% confidence interval (CI)) of 17.9 L/h (15.0-21.5) and a volume of distribution of 11.7 L (10.6-13.0) were determined.,"Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885399/),[l] / [h],17.9,42432,DB01240,Epoprostenol
,27885399,volume of distribution,A geometric mean total body clearance (95% confidence interval (CI)) of 17.9 L/h (15.0-21.5) and a volume of distribution of 11.7 L (10.6-13.0) were determined.,"Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885399/),l,11.7,42433,DB01240,Epoprostenol
,27885399,absolute oral bioavailability,The absolute oral bioavailability of selexipag (90% CI) was 49.4% (42.6-57.2).,"Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885399/),%,49.4,42434,DB01240,Epoprostenol
,27885399,bioavailability,The bioavailability of selexipag after oral administration is approximately 50%.,"Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885399/),%,50,42435,DB01240,Epoprostenol
,15243302,elimination half-life,"Secondary pharmacokinetic assessments confirmed the comparability of the two routes of administration at steady state, and also demonstrated that the elimination half-life of treprostinil was 4.4 and 4.6 hours following intravenous and subcutaneous administration, respectively.",Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15243302/),h,4.4,46923,DB01240,Epoprostenol
,15243302,elimination half-life,"Secondary pharmacokinetic assessments confirmed the comparability of the two routes of administration at steady state, and also demonstrated that the elimination half-life of treprostinil was 4.4 and 4.6 hours following intravenous and subcutaneous administration, respectively.",Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15243302/),h,4.6,46924,DB01240,Epoprostenol
,7506323,terminal half-life (t 1/2),"APS 314d pharmacokinetics was linear, and its terminal half-life (t 1/2) ranged from 0.50 +/- 0.21 to 0.91 +/- 0.27 h (mean +/- SD) independently of BPS dose.","Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506323/),h,0.50,62022,DB01240,Epoprostenol
,7506323,terminal half-life (t 1/2),"APS 314d pharmacokinetics was linear, and its terminal half-life (t 1/2) ranged from 0.50 +/- 0.21 to 0.91 +/- 0.27 h (mean +/- SD) independently of BPS dose.","Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7506323/),h,0.91,62023,DB01240,Epoprostenol
,2253664,maximum inhibition,The maximum inhibition of platelet aggregation was about 40%.,Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253664/),%,40,69915,DB01240,Epoprostenol
,2253664,total clearance,"1 h, and its total clearance amounted to 4-7 ml.min-1.kg-1.",Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253664/),[ml] / [kg·min],4-7,69916,DB01240,Epoprostenol
,1281921,Disposition half-lives,Disposition half-lives were 3 and 14 min.,Pharmacokinetics of iloprost and cicaprost in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),min,3,70550,DB01240,Epoprostenol
,1281921,Disposition half-lives,Disposition half-lives were 3 and 14 min.,Pharmacokinetics of iloprost and cicaprost in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),min,14,70551,DB01240,Epoprostenol
,1281921,Total clerance,Total clerance accounted for 152 ml/min/kg.,Pharmacokinetics of iloprost and cicaprost in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ml] / [kg·min],152,70552,DB01240,Epoprostenol
,1281921,clearance,"Total radiolabel exhibited a clearance of 35 ml/min/kg, its AUC in plasma was 146 ng-equiv.h/ml.",Pharmacokinetics of iloprost and cicaprost in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ml] / [kg·min],35,70553,DB01240,Epoprostenol
,1281921,AUC,"Total radiolabel exhibited a clearance of 35 ml/min/kg, its AUC in plasma was 146 ng-equiv.h/ml.",Pharmacokinetics of iloprost and cicaprost in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[h·ng-equiv] / [ml],146,70554,DB01240,Epoprostenol
,1281921,peak plasma levels,After ig administration Iloprost peak plasma levels of 9.2 ng/ml occurred after 5 min.,Pharmacokinetics of iloprost and cicaprost in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ng] / [ml],9.2,70555,DB01240,Epoprostenol
,1281921,Bioavailability,Bioavailability was 10%.,Pharmacokinetics of iloprost and cicaprost in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,10,70556,DB01240,Epoprostenol
,1281921,AUC,"AUC of total radiolabel was 152 ng-equiv.h/ml, showing complete absorption.",Pharmacokinetics of iloprost and cicaprost in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[h·ng-equiv] / [ml],152,70557,DB01240,Epoprostenol
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,41,70558,DB01240,Epoprostenol
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,57,70559,DB01240,Epoprostenol
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,36,70560,DB01240,Epoprostenol
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,47,70561,DB01240,Epoprostenol
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,32,70562,DB01240,Epoprostenol
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,18,70563,DB01240,Epoprostenol
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,36,70564,DB01240,Epoprostenol
,1281921,Excretion,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,25,70565,DB01240,Epoprostenol
,1281921,half-lives,Excretion of 3H-label was 41%/57% of dose (iv) and 36%/47% o.d. (ig) with the urine and 32%/18% o.d. (iv) and 36%/25% o.d. (ig) in male/female animals and proceeded for > 90% of dose fraction recovered with half-lives of 0.2-0.3 d.,Pharmacokinetics of iloprost and cicaprost in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),d,0.2-0.3,70566,DB01240,Epoprostenol
,1281921,AUC,Extrapolated AUC was 1.6 ng-equiv.,Pharmacokinetics of iloprost and cicaprost in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),ng-equiv,1.6,70567,DB01240,Epoprostenol
,1281921,total clearance,h/ml and total clearance accounted for 108 ml/min/kg.,Pharmacokinetics of iloprost and cicaprost in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ml] / [kg·min],108,70568,DB01240,Epoprostenol
,1281921,peak radioactivity plasma levels,"After ig treatment peak radioactivity plasma levels of 0.7 and 1 ng-equiv./ml were observed at 0.16 and 1 h postdose, probably due to differences between animal groups.",Pharmacokinetics of iloprost and cicaprost in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ng-equiv] / [ml],0.7,70569,DB01240,Epoprostenol
,1281921,peak radioactivity plasma levels,"After ig treatment peak radioactivity plasma levels of 0.7 and 1 ng-equiv./ml were observed at 0.16 and 1 h postdose, probably due to differences between animal groups.",Pharmacokinetics of iloprost and cicaprost in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[ng-equiv] / [ml],1,70570,DB01240,Epoprostenol
,1281921,AUC,Extrapolated AUC was 1 ng-equiv.h/ml.,Pharmacokinetics of iloprost and cicaprost in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),[h·ng-equiv] / [ml],1,70571,DB01240,Epoprostenol
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,83,70572,DB01240,Epoprostenol
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,89,70573,DB01240,Epoprostenol
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,93,70574,DB01240,Epoprostenol
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,92,70575,DB01240,Epoprostenol
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,8.3,70576,DB01240,Epoprostenol
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,5.7,70577,DB01240,Epoprostenol
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,2.6,70578,DB01240,Epoprostenol
,1281921,Excretion,"Excretion of 3H-label was mainly biliary: With the feces 83%/89% o.d. (iv) and 93%/92% o.d. (ig) were excreted by male/female animals, while 8.3%/5.7% o.d. (iv) and 2.6%/5.5% were recovered in the urine.",Pharmacokinetics of iloprost and cicaprost in mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281921/),%,5.5,70579,DB01240,Epoprostenol
,12959636,area under the concentration-time curve (AUC24),"For aspirin 80 mg/day, 24-hour area under the concentration-time curve (AUC24) was similar on days 1 and 7 (569 +/- 339 vs 605 +/- 377 microg.",Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959636/),μg,569,80752,DB01240,Epoprostenol
,12959636,area under the concentration-time curve (AUC24),"For aspirin 80 mg/day, 24-hour area under the concentration-time curve (AUC24) was similar on days 1 and 7 (569 +/- 339 vs 605 +/- 377 microg.",Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959636/),μg,605,80753,DB01240,Epoprostenol
,6351102,half-life,3H-Nileprost was absorbed after oral administration with a half-life of 23 min reaching maximum concentrations in the plasma 90 min after treatment.,"Pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6351102/),min,23,89902,DB01240,Epoprostenol
,6351102,half-lives,"After intravenous injection there was a threephasic decline in plasma levels with half-lives of 15 min, 0.9 h and 11 h, respectively.","Pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6351102/),min,15,89903,DB01240,Epoprostenol
,6351102,half-lives,"After intravenous injection there was a threephasic decline in plasma levels with half-lives of 15 min, 0.9 h and 11 h, respectively.","Pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6351102/),h,0.9,89904,DB01240,Epoprostenol
,6351102,half-lives,"After intravenous injection there was a threephasic decline in plasma levels with half-lives of 15 min, 0.9 h and 11 h, respectively.","Pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6351102/),h,11,89905,DB01240,Epoprostenol
,6351102,t 1/2,Unchanged drug was eliminated with t 1/2 = 14 min.,"Pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6351102/),min,14,89906,DB01240,Epoprostenol
,15602800,t 1/2,No statistical difference could be evidenced on any fluindione pharmacokinetic parameters between BPS and placebo phases: t 1/2 (h): 35.9 (8.2) vs. 34.0 (4.2) [90% CI 105.8 (95.5-116.2)]; T(max) (h): 2.0 (0.5-6.0) vs. 4.0 (0.5-6.0) [90% CI 136.4 (70.7-208.9)]; Cmax (mg/L): 3.1 (0.6) vs. 2.9 (0.5) [90% CI 94.1 (85.8-103.2)]; AUC 0-inf (mg/h/L): 117.0 (31.5) vs. 113.9 (33.8) [90% CI 97.6 (87.5-108.8)].,Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602800/),h,35.9,101054,DB01240,Epoprostenol
,15602800,t 1/2,No statistical difference could be evidenced on any fluindione pharmacokinetic parameters between BPS and placebo phases: t 1/2 (h): 35.9 (8.2) vs. 34.0 (4.2) [90% CI 105.8 (95.5-116.2)]; T(max) (h): 2.0 (0.5-6.0) vs. 4.0 (0.5-6.0) [90% CI 136.4 (70.7-208.9)]; Cmax (mg/L): 3.1 (0.6) vs. 2.9 (0.5) [90% CI 94.1 (85.8-103.2)]; AUC 0-inf (mg/h/L): 117.0 (31.5) vs. 113.9 (33.8) [90% CI 97.6 (87.5-108.8)].,Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602800/),h,34.0,101055,DB01240,Epoprostenol
,15602800,T(max),No statistical difference could be evidenced on any fluindione pharmacokinetic parameters between BPS and placebo phases: t 1/2 (h): 35.9 (8.2) vs. 34.0 (4.2) [90% CI 105.8 (95.5-116.2)]; T(max) (h): 2.0 (0.5-6.0) vs. 4.0 (0.5-6.0) [90% CI 136.4 (70.7-208.9)]; Cmax (mg/L): 3.1 (0.6) vs. 2.9 (0.5) [90% CI 94.1 (85.8-103.2)]; AUC 0-inf (mg/h/L): 117.0 (31.5) vs. 113.9 (33.8) [90% CI 97.6 (87.5-108.8)].,Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602800/),h,2.0,101056,DB01240,Epoprostenol
,15602800,T(max),No statistical difference could be evidenced on any fluindione pharmacokinetic parameters between BPS and placebo phases: t 1/2 (h): 35.9 (8.2) vs. 34.0 (4.2) [90% CI 105.8 (95.5-116.2)]; T(max) (h): 2.0 (0.5-6.0) vs. 4.0 (0.5-6.0) [90% CI 136.4 (70.7-208.9)]; Cmax (mg/L): 3.1 (0.6) vs. 2.9 (0.5) [90% CI 94.1 (85.8-103.2)]; AUC 0-inf (mg/h/L): 117.0 (31.5) vs. 113.9 (33.8) [90% CI 97.6 (87.5-108.8)].,Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602800/),h,4.0,101057,DB01240,Epoprostenol
,15602800,Cmax,No statistical difference could be evidenced on any fluindione pharmacokinetic parameters between BPS and placebo phases: t 1/2 (h): 35.9 (8.2) vs. 34.0 (4.2) [90% CI 105.8 (95.5-116.2)]; T(max) (h): 2.0 (0.5-6.0) vs. 4.0 (0.5-6.0) [90% CI 136.4 (70.7-208.9)]; Cmax (mg/L): 3.1 (0.6) vs. 2.9 (0.5) [90% CI 94.1 (85.8-103.2)]; AUC 0-inf (mg/h/L): 117.0 (31.5) vs. 113.9 (33.8) [90% CI 97.6 (87.5-108.8)].,Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602800/),[mg] / [l],3.1,101058,DB01240,Epoprostenol
,15602800,Cmax,No statistical difference could be evidenced on any fluindione pharmacokinetic parameters between BPS and placebo phases: t 1/2 (h): 35.9 (8.2) vs. 34.0 (4.2) [90% CI 105.8 (95.5-116.2)]; T(max) (h): 2.0 (0.5-6.0) vs. 4.0 (0.5-6.0) [90% CI 136.4 (70.7-208.9)]; Cmax (mg/L): 3.1 (0.6) vs. 2.9 (0.5) [90% CI 94.1 (85.8-103.2)]; AUC 0-inf (mg/h/L): 117.0 (31.5) vs. 113.9 (33.8) [90% CI 97.6 (87.5-108.8)].,Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602800/),[mg] / [l],2.9,101059,DB01240,Epoprostenol
,15602800,AUC 0-inf,No statistical difference could be evidenced on any fluindione pharmacokinetic parameters between BPS and placebo phases: t 1/2 (h): 35.9 (8.2) vs. 34.0 (4.2) [90% CI 105.8 (95.5-116.2)]; T(max) (h): 2.0 (0.5-6.0) vs. 4.0 (0.5-6.0) [90% CI 136.4 (70.7-208.9)]; Cmax (mg/L): 3.1 (0.6) vs. 2.9 (0.5) [90% CI 94.1 (85.8-103.2)]; AUC 0-inf (mg/h/L): 117.0 (31.5) vs. 113.9 (33.8) [90% CI 97.6 (87.5-108.8)].,Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602800/),[mg] / [h·l],117.0,101060,DB01240,Epoprostenol
,15602800,AUC 0-inf,No statistical difference could be evidenced on any fluindione pharmacokinetic parameters between BPS and placebo phases: t 1/2 (h): 35.9 (8.2) vs. 34.0 (4.2) [90% CI 105.8 (95.5-116.2)]; T(max) (h): 2.0 (0.5-6.0) vs. 4.0 (0.5-6.0) [90% CI 136.4 (70.7-208.9)]; Cmax (mg/L): 3.1 (0.6) vs. 2.9 (0.5) [90% CI 94.1 (85.8-103.2)]; AUC 0-inf (mg/h/L): 117.0 (31.5) vs. 113.9 (33.8) [90% CI 97.6 (87.5-108.8)].,Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602800/),[mg] / [h·l],113.9,101061,DB01240,Epoprostenol
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],942,102658,DB01240,Epoprostenol
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],884,102659,DB01240,Epoprostenol
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],537,102660,DB01240,Epoprostenol
,23328389,area under the curve (AUC0-12),"After chronic twice-daily oral dosing of treprostinil diolamine, mean area under the curve (AUC0-12) of treprostinil increased from 5244 to 20,4086 pg·hr-·mL- and mean maximum observed plasma concentration (Cmax) increased from 1383 to 33588 pg/mL.",Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328389/),hr-·ml·pg,52,106844,DB01240,Epoprostenol
,23328389,area under the curve (AUC0-12),"After chronic twice-daily oral dosing of treprostinil diolamine, mean area under the curve (AUC0-12) of treprostinil increased from 5244 to 20,4086 pg·hr-·mL- and mean maximum observed plasma concentration (Cmax) increased from 1383 to 33588 pg/mL.",Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328389/),hr-·ml·pg,20,106845,DB01240,Epoprostenol
,23328389,maximum observed plasma concentration (Cmax),"After chronic twice-daily oral dosing of treprostinil diolamine, mean area under the curve (AUC0-12) of treprostinil increased from 5244 to 20,4086 pg·hr-·mL- and mean maximum observed plasma concentration (Cmax) increased from 1383 to 33588 pg/mL.",Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328389/),[pg] / [ml],138,106846,DB01240,Epoprostenol
,3512745,half-life of the terminal elimination phase,The half-life of the terminal elimination phase was 2.7 minutes.,Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512745/),min,2.7,108574,DB01240,Epoprostenol
,3512745,systemic clearance,"The calculated systemic clearance and whole body volume of distribution were 93 ml/kg/min and 357 ml/kg, respectively.",Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512745/),[ml] / [kg·min],93,108575,DB01240,Epoprostenol
,3512745,whole body volume of distribution,"The calculated systemic clearance and whole body volume of distribution were 93 ml/kg/min and 357 ml/kg, respectively.",Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512745/),[ml] / [kg],357,108576,DB01240,Epoprostenol
greater,3512745,steady-state plasma concentrations,"At steady-state plasma concentrations of PGI2 greater than 0.1 ng/ml, the mean arterial blood pressure decreased in a concentration-dependent manner, reaching a decrease of 45 mm Hg when the plasma concentration was 7.6 ng/ml.",Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512745/),[ng] / [ml],0,108577,DB01240,Epoprostenol
over,28277164,total recoveries,"2. After oral administration of [14C]selexipag, selexipag was well absorbed in rats and dogs with total recoveries of over 90% of the dose, mainly in the faeces.","Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28277164/),%,90,113282,DB01240,Epoprostenol
,2829267,Plasma levels,"Plasma levels 5 min after intravenous administration of ZK 93 426 were 16 +/- 10 ng/ml and 52 +/- 31 ng/ml for 0.01 mg/kg and 0.04 mg/kg, respectively.","Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93,426: preliminary observations on psychotropic activity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829267/),[ng] / [ml],16,114268,DB01240,Epoprostenol
,2829267,Plasma levels,"Plasma levels 5 min after intravenous administration of ZK 93 426 were 16 +/- 10 ng/ml and 52 +/- 31 ng/ml for 0.01 mg/kg and 0.04 mg/kg, respectively.","Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93,426: preliminary observations on psychotropic activity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829267/),[ng] / [ml],52,114269,DB01240,Epoprostenol
,2829267,Total clearance,Total clearance was calculated as 46 +/- 22 ml/min/kg (0.04 mg/kg).,"Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93,426: preliminary observations on psychotropic activity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829267/),[ml] / [kg·min],46,114270,DB01240,Epoprostenol
,29421665,EC50,The concentration of TRE in the plasma at which PAP was reduced by 50% was approximately 60-fold lower for INS1009 (EC50 = 0.08 ng/mL) as compared to i.v. TRE (EC50 = 4.9 ng/mL).,Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29421665/),[ng] / [ml],0.08,120107,DB01240,Epoprostenol
,29421665,EC50,The concentration of TRE in the plasma at which PAP was reduced by 50% was approximately 60-fold lower for INS1009 (EC50 = 0.08 ng/mL) as compared to i.v. TRE (EC50 = 4.9 ng/mL).,Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29421665/),[ng] / [ml],4.9,120108,DB01240,Epoprostenol
,29421665,EC50,The concentration of TRE in the plasma at which RVPP was reduced by 50% was approximately 550-fold lower for INS1009 (EC50 = 0.0075 ng/mL) as compared to i.v. TRE (EC50 = 4.1 ng/mL).,Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29421665/),[ng] / [ml],0.0075,120109,DB01240,Epoprostenol
,29421665,EC50,The concentration of TRE in the plasma at which RVPP was reduced by 50% was approximately 550-fold lower for INS1009 (EC50 = 0.0075 ng/mL) as compared to i.v. TRE (EC50 = 4.1 ng/mL).,Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29421665/),[ng] / [ml],4.1,120110,DB01240,Epoprostenol
,2657866,half-lives,"At the end of the infusion plasma levels of approximately 100 pg/ml were reached, declining biphasically with half-lives of 3-4 min and 64 +/- 21 min.",Pharmacokinetics of 3H-cicaprost in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2657866/),min,3-4,122536,DB01240,Epoprostenol
,2657866,half-lives,"At the end of the infusion plasma levels of approximately 100 pg/ml were reached, declining biphasically with half-lives of 3-4 min and 64 +/- 21 min.",Pharmacokinetics of 3H-cicaprost in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2657866/),min,64,122537,DB01240,Epoprostenol
,2657866,Total clearance,Total clearance was 3.8 +/- 0.5 ml/min/kg.,Pharmacokinetics of 3H-cicaprost in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2657866/),[ml] / [kg·min],3.8,122538,DB01240,Epoprostenol
,2657866,peak plasma levels,The oral dosage resulted in peak plasma levels of 251 +/- 90 pg/ml occurring at 23 +/- 5 min post dose.,Pharmacokinetics of 3H-cicaprost in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2657866/),[pg] / [ml],251,122539,DB01240,Epoprostenol
,2657866,terminal half-life,The terminal half-life in the plasma was 115 +/- 30 min.,Pharmacokinetics of 3H-cicaprost in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2657866/),min,115,122540,DB01240,Epoprostenol
,33583799,Cmax,"The Cmax of BPS was (601.14 ± 214.81) pg/mL, the Tmax was (0.58 ± 0.48) h, and AUC0-t was (1020.41±214.63) pg/mL•h.",Pharmacokinetics and vasodilating effect study of beraprost sodium in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33583799/),[pg] / [ml],601.14,125741,DB01240,Epoprostenol
,33583799,Tmax,"The Cmax of BPS was (601.14 ± 214.81) pg/mL, the Tmax was (0.58 ± 0.48) h, and AUC0-t was (1020.41±214.63) pg/mL•h.",Pharmacokinetics and vasodilating effect study of beraprost sodium in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33583799/),h,0.58,125742,DB01240,Epoprostenol
,33583799,AUC0-t,"The Cmax of BPS was (601.14 ± 214.81) pg/mL, the Tmax was (0.58 ± 0.48) h, and AUC0-t was (1020.41±214.63) pg/mL•h.",Pharmacokinetics and vasodilating effect study of beraprost sodium in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33583799/),[pg] / [h·ml],1020.41,125743,DB01240,Epoprostenol
,17034310,maximum intravascular concentrations,"Similarly, dose-dependent appearance of iloprost in the recirculating perfusate was noted, with maximum intravascular concentrations of iloprost ranging at 140, 510, and 1163 pg/mL at the same time period.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),[pg] / [ml],140,130012,DB01240,Epoprostenol
,17034310,maximum intravascular concentrations,"Similarly, dose-dependent appearance of iloprost in the recirculating perfusate was noted, with maximum intravascular concentrations of iloprost ranging at 140, 510, and 1163 pg/mL at the same time period.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),[pg] / [ml],510,130013,DB01240,Epoprostenol
,17034310,maximum intravascular concentrations,"Similarly, dose-dependent appearance of iloprost in the recirculating perfusate was noted, with maximum intravascular concentrations of iloprost ranging at 140, 510, and 1163 pg/mL at the same time period.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),[pg] / [ml],1163,130014,DB01240,Epoprostenol
,17034310,bioavailability,"(i) The bioavailability (i.e., the percentage of aerosolized iloprost appearing intravascularly) decreased from 76% at the lowest to 33% at the highest iloprost dosage.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),%,76,130015,DB01240,Epoprostenol
,17034310,bioavailability,"(i) The bioavailability (i.e., the percentage of aerosolized iloprost appearing intravascularly) decreased from 76% at the lowest to 33% at the highest iloprost dosage.",Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034310/),%,33,130016,DB01240,Epoprostenol
,15914004,IC50,The optimized diphenylcarbamate type compound FK-788: (R)-4 exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K(i) values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family.,Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15914004/),nM,18,134258,DB01240,Epoprostenol
,15914004,K(i),The optimized diphenylcarbamate type compound FK-788: (R)-4 exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K(i) values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family.,Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15914004/),nM,20,134259,DB01240,Epoprostenol
,12775969,Area under the effect-time curve (AUEC(0-1)),"Area under the effect-time curve (AUEC(0-1)) and maximum effect over the entire sampling phase (E(max)) for warfarin INR were 219.58 and 2.071 with treprostinil and 218.93 and 2.041 with vehicle, respectively.",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),,219.58,138047,DB01240,Epoprostenol
,12775969,Area under the effect-time curve (AUEC(0-1)),"Area under the effect-time curve (AUEC(0-1)) and maximum effect over the entire sampling phase (E(max)) for warfarin INR were 219.58 and 2.071 with treprostinil and 218.93 and 2.041 with vehicle, respectively.",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),,218.93,138048,DB01240,Epoprostenol
,12775969,maximum effect over the entire sampling phase (E(max)),"Area under the effect-time curve (AUEC(0-1)) and maximum effect over the entire sampling phase (E(max)) for warfarin INR were 219.58 and 2.071 with treprostinil and 218.93 and 2.041 with vehicle, respectively.",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),,2.071,138049,DB01240,Epoprostenol
,12775969,maximum effect over the entire sampling phase (E(max)),"Area under the effect-time curve (AUEC(0-1)) and maximum effect over the entire sampling phase (E(max)) for warfarin INR were 219.58 and 2.071 with treprostinil and 218.93 and 2.041 with vehicle, respectively.",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),,2.041,138050,DB01240,Epoprostenol
,12775969,time to attain the peak concentration,"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),h,1.9,138051,DB01240,Epoprostenol
,12775969,half-life,"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),h,51.688,138052,DB01240,Epoprostenol
,12775969,half-life,"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),h,1.5,138053,DB01240,Epoprostenol
,12775969,half-life,"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),h,52.579,138054,DB01240,Epoprostenol
,12775969,elimination rate constant (k(el)),"Mean time to attain the peak concentration of R-enantiomer of warfarin (T(max)), half-life, and elimination rate constant (k(el)) were 1.9 hours, 51.688 hours, and 0.0137 per hour, respectively, in the presence of treprostinil and 1.5 hours, 52.579 hours, and 0.0137 per hour, respectively, in the presence of vehicle (control).",Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12775969/),1/[h],0.0137,138055,DB01240,Epoprostenol
,3513767,peak plasma levels,After dazmegrel 50-200 mg p.o. peak plasma levels of 0.7-3 mu/ml were reached within 1 hr.,"Effects on prostanoid formation and pharmacokinetics of dazmegrel (UK-38,485), a novel thromboxane synthase inhibitor, in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3513767/),[mu] / [ml],0.7-3,140947,DB01240,Epoprostenol
,3513767,half life,Elimination was of first order with a half life of 0.88 +/- 0.17 hr.,"Effects on prostanoid formation and pharmacokinetics of dazmegrel (UK-38,485), a novel thromboxane synthase inhibitor, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3513767/),h,0.88,140948,DB01240,Epoprostenol
,32398473,peak,"In cohort 1, oral dosing led to higher peak (5.9 ng/mL) and lower trough (1 ng/mL) concentrations than parenteral (peak 5.4 ng/mL and trough 4.2 ng/mL), but a lower mean concentration (3.61 vs. 4.46 ng/mL), likely due to variable metabolism and noncomparable dosing.",Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32398473/),[ng] / [ml],5.9,141861,DB01240,Epoprostenol
,32398473,trough,"In cohort 1, oral dosing led to higher peak (5.9 ng/mL) and lower trough (1 ng/mL) concentrations than parenteral (peak 5.4 ng/mL and trough 4.2 ng/mL), but a lower mean concentration (3.61 vs. 4.46 ng/mL), likely due to variable metabolism and noncomparable dosing.",Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32398473/),[ng] / [ml],1,141862,DB01240,Epoprostenol
,32398473,peak,"In cohort 1, oral dosing led to higher peak (5.9 ng/mL) and lower trough (1 ng/mL) concentrations than parenteral (peak 5.4 ng/mL and trough 4.2 ng/mL), but a lower mean concentration (3.61 vs. 4.46 ng/mL), likely due to variable metabolism and noncomparable dosing.",Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32398473/),[ng] / [ml],5.4,141863,DB01240,Epoprostenol
,32398473,trough,"In cohort 1, oral dosing led to higher peak (5.9 ng/mL) and lower trough (1 ng/mL) concentrations than parenteral (peak 5.4 ng/mL and trough 4.2 ng/mL), but a lower mean concentration (3.61 vs. 4.46 ng/mL), likely due to variable metabolism and noncomparable dosing.",Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32398473/),[ng] / [ml],4.2,141864,DB01240,Epoprostenol
,32398473,mean concentration,"In cohort 1, oral dosing led to higher peak (5.9 ng/mL) and lower trough (1 ng/mL) concentrations than parenteral (peak 5.4 ng/mL and trough 4.2 ng/mL), but a lower mean concentration (3.61 vs. 4.46 ng/mL), likely due to variable metabolism and noncomparable dosing.",Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32398473/),[ng] / [ml],3.61,141865,DB01240,Epoprostenol
,32398473,mean concentration,"In cohort 1, oral dosing led to higher peak (5.9 ng/mL) and lower trough (1 ng/mL) concentrations than parenteral (peak 5.4 ng/mL and trough 4.2 ng/mL), but a lower mean concentration (3.61 vs. 4.46 ng/mL), likely due to variable metabolism and noncomparable dosing.",Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32398473/),[ng] / [ml],4.46,141866,DB01240,Epoprostenol
,2665172,arterial: portal AUC ratios,"In three pigs which received all three dosage regimens, the arterial: portal AUC ratios were 0.48 +/- 0.05 after 50 mg single dose, 0.52 +/- 0.02 after 100 mg single dose and 0.47 +/- 0.02 after 100 mg daily for 1 week.","Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2665172/),,0.48,143245,DB01240,Epoprostenol
,2665172,arterial: portal AUC ratios,"In three pigs which received all three dosage regimens, the arterial: portal AUC ratios were 0.48 +/- 0.05 after 50 mg single dose, 0.52 +/- 0.02 after 100 mg single dose and 0.47 +/- 0.02 after 100 mg daily for 1 week.","Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2665172/),,0.52,143246,DB01240,Epoprostenol
,2665172,arterial: portal AUC ratios,"In three pigs which received all three dosage regimens, the arterial: portal AUC ratios were 0.48 +/- 0.05 after 50 mg single dose, 0.52 +/- 0.02 after 100 mg single dose and 0.47 +/- 0.02 after 100 mg daily for 1 week.","Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2665172/),,0.47,143247,DB01240,Epoprostenol
less,6374676,limit of detection,The limit of detection is less than 10 pg/ml.,"Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374676/),[pg] / [ml],10,152079,DB01240,Epoprostenol
,6374676,half-lives,"Following intravenous injection of 200 micrograms/kg to female Wistar rats, a three-phasic decline in plasma levels was observed with half-lives of 10 min, 30 min and 7.4 h.","Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374676/),min,10,152080,DB01240,Epoprostenol
,6374676,half-lives,"Following intravenous injection of 200 micrograms/kg to female Wistar rats, a three-phasic decline in plasma levels was observed with half-lives of 10 min, 30 min and 7.4 h.","Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374676/),min,30,152081,DB01240,Epoprostenol
,6374676,half-lives,"Following intravenous injection of 200 micrograms/kg to female Wistar rats, a three-phasic decline in plasma levels was observed with half-lives of 10 min, 30 min and 7.4 h.","Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374676/),h,7.4,152082,DB01240,Epoprostenol
,6374676,maximum concentrations,"Oral doses of 200 and 2,000 micrograms/kg were very rapidly absorbed exhibiting maximum concentrations in the plasma of 20 and 30 ng/ml as early as 5 min postadministration .","Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374676/),[ng] / [ml],20,152083,DB01240,Epoprostenol
,6374676,maximum concentrations,"Oral doses of 200 and 2,000 micrograms/kg were very rapidly absorbed exhibiting maximum concentrations in the plasma of 20 and 30 ng/ml as early as 5 min postadministration .","Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374676/),[ng] / [ml],30,152084,DB01240,Epoprostenol
,6374676,Bioavailability,Bioavailability of nileprost was calculated to be 21 and 13% of the dose.,"Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374676/),%,21,152085,DB01240,Epoprostenol
,6374676,Bioavailability,Bioavailability of nileprost was calculated to be 21 and 13% of the dose.,"Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374676/),%,13,152086,DB01240,Epoprostenol
,6374676,disposition half-life,The disposition half-life was 5-7 h in both cases.,"Development of a radioimmunoassay and its application to the pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374676/),h,5-7,152087,DB01240,Epoprostenol
,6193537,half-lives,"Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),min,45,152625,DB01240,Epoprostenol
,6193537,half-lives,"Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),h,4.3,152626,DB01240,Epoprostenol
,6193537,half-lives,"Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),d,1.7,152627,DB01240,Epoprostenol
,6193537,half-life,The half-life of the unchanged drug was 13 min.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),min,13,152628,DB01240,Epoprostenol
,6193537,maximum plasma levels,Almost 10% of an oral dose of 200 microgram/kg were bioavailable exhibiting maximum plasma levels of 5.7 +/- 3.6 ng/ml.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),[ng] / [ml],5.7,152629,DB01240,Epoprostenol
,27681484,Cmax,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[pg] / [ml],84.9,158026,DB01240,Epoprostenol
,27681484,Cmax,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[pg] / [ml],119.8,158027,DB01240,Epoprostenol
,27681484,Cmax,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[pg] / [ml],190.6,158028,DB01240,Epoprostenol
,27681484,Cmax,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[pg] / [ml],240.2,158029,DB01240,Epoprostenol
,27681484,AUC0-48h,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[h·pg] / [ml],978,158030,DB01240,Epoprostenol
,27681484,AUC0-48h,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[h·pg] / [ml],1252,158031,DB01240,Epoprostenol
,27681484,AUC0-48h,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[h·pg] / [ml],1862,158032,DB01240,Epoprostenol
,27681484,AUC0-48h,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[h·pg] / [ml],1766,158033,DB01240,Epoprostenol
,27681484,cumulative urinary excretion rates,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),%,0.704,158034,DB01240,Epoprostenol
,27681484,cumulative urinary excretion rates,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),%,0.638,158035,DB01240,Epoprostenol
,27681484,cumulative urinary excretion rates,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),%,0.485,158036,DB01240,Epoprostenol
,27681484,cumulative urinary excretion rates,"The Cmax values (mean ± SD) of BPS in stage 1, 2, 3, and 4 CKD, respectively, were 84.9 ± 22.9, 119.8 ± 36.4, 190.6 ± 137.3, and 240.2 ± 110.5 pg/mL; its AUC0-48h were 978 ± 226, 1252 ± 427, 1862 ± 964, and 1766 ± 806 pg·h/mL, respectively, and its cumulative urinary excretion rates were 0.704 ± 0.351%, 0.638 ± 0.292%, 0.485 ± 0.294%, and 0.159 ± 0.136%.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),%,0.159,158037,DB01240,Epoprostenol
,27681484,Cmax,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[pg] / [ml],22.4,158038,DB01240,Epoprostenol
,27681484,Cmax,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[pg] / [ml],30.8,158039,DB01240,Epoprostenol
,27681484,Cmax,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[pg] / [ml],46.7,158040,DB01240,Epoprostenol
,27681484,Cmax,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[pg] / [ml],54.4,158041,DB01240,Epoprostenol
,27681484,AUC0-48h,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[h·pg] / [ml],155,158042,DB01240,Epoprostenol
,27681484,AUC0-48h,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[h·pg] / [ml],226,158043,DB01240,Epoprostenol
,27681484,AUC0-48h,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[h·pg] / [ml],341,158044,DB01240,Epoprostenol
,27681484,AUC0-48h,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),[h·pg] / [ml],329,158045,DB01240,Epoprostenol
,27681484,cumulative urinary excretion rates,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),%,0.428,158046,DB01240,Epoprostenol
,27681484,cumulative urinary excretion rates,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),%,0.349,158047,DB01240,Epoprostenol
,27681484,cumulative urinary excretion rates,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),%,0.356,158048,DB01240,Epoprostenol
,27681484,cumulative urinary excretion rates,"The Cmax values of BPS-314d were 22.4 ± 6.4, 30.8 ± 8.5, 46.7 ± 30.6, and 54.4 ± 25.2 pg/mL, its AUC0-48h were 155 ± 56, 226 ± 67, 341 ± 176, and 329 ± 143 pg·h/mL, and its cumulative urinary excretion rates were 0.428 ± 0.242%, 0.349 ± 0.179%, 0.356 ± 0.270%, and 0.096 ± 0.099%, respectively.",The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27681484/),%,0.096,158049,DB01240,Epoprostenol
,25850750,half-lives,"Maximum plasma concentrations of selexipag and ACT-333679 were reached within 2.5 and 4 h, respectively, with mean half-lives of 0.7-2.3 and 9.4-14.22 h.",Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25850750/),h,0.7-2.3,163945,DB01240,Epoprostenol
,25850750,half-lives,"Maximum plasma concentrations of selexipag and ACT-333679 were reached within 2.5 and 4 h, respectively, with mean half-lives of 0.7-2.3 and 9.4-14.22 h.",Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25850750/),h,9.4-14.22,163946,DB01240,Epoprostenol
,1586379,ratio of IC50's,"The ratio of IC50's of PGI2 production to TXA2 production of KC-764 was 175 in rats, 72 in rabbits and 65 in dogs, respectively.","Antiplatelet effects of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in relation to its disposition in rats, rabbits and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586379/),,175,171056,DB01240,Epoprostenol
,1586379,ratio of IC50's,"The ratio of IC50's of PGI2 production to TXA2 production of KC-764 was 175 in rats, 72 in rabbits and 65 in dogs, respectively.","Antiplatelet effects of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in relation to its disposition in rats, rabbits and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586379/),,72,171057,DB01240,Epoprostenol
,1586379,ratio of IC50's,"The ratio of IC50's of PGI2 production to TXA2 production of KC-764 was 175 in rats, 72 in rabbits and 65 in dogs, respectively.","Antiplatelet effects of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in relation to its disposition in rats, rabbits and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586379/),,65,171058,DB01240,Epoprostenol
,15102871,apparent plasma clearance,"Variation in apparent plasma clearance for the four doses was small (i.e., 9.77-10.4 mL/kg/min).",Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102871/),[ml] / [kg·min],9.77-10.4,173180,DB01240,Epoprostenol
,15102871,terminal half-life,The terminal half-life of treprostinil was 2.93 hours.,Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102871/),h,2.93,173181,DB01240,Epoprostenol
,15102871,elimination half-life,"In addition, the elimination half-life was about 3 hours.",Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102871/),h,3,173182,DB01240,Epoprostenol
,14681345,Cmax,Acute administration of treprostinil administered by subcutaneous infusion at a rate of 15 ng/kg/min for 150 minutes achieved a mean Cmax of 1.47 ng/mL.,Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681345/),[ng] / [ml],1.47,176409,DB01240,Epoprostenol
,14681345,AUC infinity,"Mean AUC infinity values for intravenous and subcutaneous dosing were 3.52 and 3.97 ng.h/mL, respectively, resulting in a mean apparent absolute bioavailability of 113% for subcutaneous administration.",Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681345/),[h·ng] / [ml],3.52,176410,DB01240,Epoprostenol
,14681345,AUC infinity,"Mean AUC infinity values for intravenous and subcutaneous dosing were 3.52 and 3.97 ng.h/mL, respectively, resulting in a mean apparent absolute bioavailability of 113% for subcutaneous administration.",Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681345/),[h·ng] / [ml],3.97,176411,DB01240,Epoprostenol
,14681345,apparent absolute bioavailability,"Mean AUC infinity values for intravenous and subcutaneous dosing were 3.52 and 3.97 ng.h/mL, respectively, resulting in a mean apparent absolute bioavailability of 113% for subcutaneous administration.",Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681345/),%,113,176412,DB01240,Epoprostenol
,14681345,apparent elimination half-life,"The mean apparent elimination half-life of treprostinil following subcutaneous administration was 1.38 hours, compared to 0.87 hours following intravenous administration.",Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681345/),h,1.38,176413,DB01240,Epoprostenol
,14681345,apparent elimination half-life,"The mean apparent elimination half-life of treprostinil following subcutaneous administration was 1.38 hours, compared to 0.87 hours following intravenous administration.",Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681345/),h,0.87,176414,DB01240,Epoprostenol
,7692471,Total clearance,"Total clearance of the pro-drug accounted for 170, 62 and 66 ml/min/kg in rat, monkey and man.",Bioactivation of eptaloprost in animals and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),[ml] / [kg·min],170,180634,DB01240,Epoprostenol
,7692471,Total clearance,"Total clearance of the pro-drug accounted for 170, 62 and 66 ml/min/kg in rat, monkey and man.",Bioactivation of eptaloprost in animals and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),[ml] / [kg·min],62,180635,DB01240,Epoprostenol
,7692471,Total clearance,"Total clearance of the pro-drug accounted for 170, 62 and 66 ml/min/kg in rat, monkey and man.",Bioactivation of eptaloprost in animals and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),[ml] / [kg·min],66,180636,DB01240,Epoprostenol
,7692471,half-lives,"Disposition of eptaloprost exhibited half-lives of 0.1 to 0.5 h and mean residence times accounted for 0.15, 0.4 and 0.6 h in the three species.",Bioactivation of eptaloprost in animals and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),h,0.1 to 0.5,180637,DB01240,Epoprostenol
,7692471,mean residence times,"Disposition of eptaloprost exhibited half-lives of 0.1 to 0.5 h and mean residence times accounted for 0.15, 0.4 and 0.6 h in the three species.",Bioactivation of eptaloprost in animals and man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),h,0.15,180638,DB01240,Epoprostenol
,7692471,mean residence times,"Disposition of eptaloprost exhibited half-lives of 0.1 to 0.5 h and mean residence times accounted for 0.15, 0.4 and 0.6 h in the three species.",Bioactivation of eptaloprost in animals and man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),h,0.4,180639,DB01240,Epoprostenol
,7692471,mean residence times,"Disposition of eptaloprost exhibited half-lives of 0.1 to 0.5 h and mean residence times accounted for 0.15, 0.4 and 0.6 h in the three species.",Bioactivation of eptaloprost in animals and man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7692471/),h,0.6,180640,DB01240,Epoprostenol
,8040351,specific activity,Cicaprost-[3H]-methylester with a specific activity of 819 GBq/mmol was used as a tracer.,Development and validation of a sensitive and specific radioimmunoassay for the determination of cicaprost in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040351/),[gbq] / [mM],819,182248,DB01240,Epoprostenol
,8040351,Extraction recovery,Extraction recovery of Cicaprost was approximately 90% at pH approximately 2.,Development and validation of a sensitive and specific radioimmunoassay for the determination of cicaprost in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040351/),%,90,182249,DB01240,Epoprostenol
,8040351,detection limit,The detection limit of the assay was 10-20 pg/ml plasma.,Development and validation of a sensitive and specific radioimmunoassay for the determination of cicaprost in biological samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8040351/),[pg] / [ml],10-20,182250,DB01240,Epoprostenol
,6189134,limit of detection,The limit of detection is 0.5 ng/ml.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),[ng] / [ml],0.5,195881,DB01240,Epoprostenol
,6189134,half-lives,After intravenous administration of 200 micrograms/kg to female Wistar rats a biphasic decline of the drug concentration in the plasma was observed with half-lives of 5 min and 3 h.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),min,5,195882,DB01240,Epoprostenol
,6189134,half-lives,After intravenous administration of 200 micrograms/kg to female Wistar rats a biphasic decline of the drug concentration in the plasma was observed with half-lives of 5 min and 3 h.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),h,3,195883,DB01240,Epoprostenol
,6189134,maximum plasma levels,Oral doses of 200 and 2000 micrograms/kg were very rapidly absorbed reaching maximum plasma levels of 3 and 32 ng/ml as early as 10-15 min p.admin..,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),[ng] / [ml],3,195884,DB01240,Epoprostenol
,6189134,maximum plasma levels,Oral doses of 200 and 2000 micrograms/kg were very rapidly absorbed reaching maximum plasma levels of 3 and 32 ng/ml as early as 10-15 min p.admin..,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),[ng] / [ml],32,195885,DB01240,Epoprostenol
,6189134,Bioavailability,Bioavailability at the two dose levels was calculated to be 8 and 13% of dose.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),%,8,195886,DB01240,Epoprostenol
,6189134,Bioavailability,Bioavailability at the two dose levels was calculated to be 8 and 13% of dose.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6189134/),%,13,195887,DB01240,Epoprostenol
,25843412,AUC0-6h,"In healthy controls and diabetic patients, treprostinil 250µM induced a significant increase in CVC compared with NaCl (for diabetic patients, AUC0-6h was 19970±8697; versus 2893±5481%BL.min, respectively; P=0.002).","Cutaneous iontophoresis of treprostinil, a prostacyclin analog, increases microvascular blood flux in diabetic malleolus area. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843412/),%bl·min,19970,201776,DB01240,Epoprostenol
,25843412,AUC0-6h,"In healthy controls and diabetic patients, treprostinil 250µM induced a significant increase in CVC compared with NaCl (for diabetic patients, AUC0-6h was 19970±8697; versus 2893±5481%BL.min, respectively; P=0.002).","Cutaneous iontophoresis of treprostinil, a prostacyclin analog, increases microvascular blood flux in diabetic malleolus area. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25843412/),%bl·min,2893,201777,DB01240,Epoprostenol
,23188123,Cmax,"The median Cmax, AUC0-inf, and t1/2 of treprostinil were 680 pg/mL, 3240 hours pg/mL, and 2.35 hours, respectively, in ESRD subjects dosed after dialysis and were 551 pg/mL, 3152 hours pg/mL, and 2.05 hours, respectively, in ESRD subjects dosed before dialysis.",Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23188123/),[pg] / [ml],680,208963,DB01240,Epoprostenol
,23188123,Cmax,"The median Cmax, AUC0-inf, and t1/2 of treprostinil were 680 pg/mL, 3240 hours pg/mL, and 2.35 hours, respectively, in ESRD subjects dosed after dialysis and were 551 pg/mL, 3152 hours pg/mL, and 2.05 hours, respectively, in ESRD subjects dosed before dialysis.",Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23188123/),[pg] / [ml],551,208964,DB01240,Epoprostenol
,23188123,AUC0-inf,"The median Cmax, AUC0-inf, and t1/2 of treprostinil were 680 pg/mL, 3240 hours pg/mL, and 2.35 hours, respectively, in ESRD subjects dosed after dialysis and were 551 pg/mL, 3152 hours pg/mL, and 2.05 hours, respectively, in ESRD subjects dosed before dialysis.",Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23188123/),[h·pg] / [ml],3240,208965,DB01240,Epoprostenol
,23188123,AUC0-inf,"The median Cmax, AUC0-inf, and t1/2 of treprostinil were 680 pg/mL, 3240 hours pg/mL, and 2.35 hours, respectively, in ESRD subjects dosed after dialysis and were 551 pg/mL, 3152 hours pg/mL, and 2.05 hours, respectively, in ESRD subjects dosed before dialysis.",Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23188123/),[pg] / [ml],551,208966,DB01240,Epoprostenol
,23188123,AUC0-inf,"The median Cmax, AUC0-inf, and t1/2 of treprostinil were 680 pg/mL, 3240 hours pg/mL, and 2.35 hours, respectively, in ESRD subjects dosed after dialysis and were 551 pg/mL, 3152 hours pg/mL, and 2.05 hours, respectively, in ESRD subjects dosed before dialysis.",Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23188123/),[h·pg] / [ml],3152,208967,DB01240,Epoprostenol
,23188123,AUC0-inf,"The median Cmax, AUC0-inf, and t1/2 of treprostinil were 680 pg/mL, 3240 hours pg/mL, and 2.35 hours, respectively, in ESRD subjects dosed after dialysis and were 551 pg/mL, 3152 hours pg/mL, and 2.05 hours, respectively, in ESRD subjects dosed before dialysis.",Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23188123/),h,2.05,208968,DB01240,Epoprostenol
,23188123,t1/2,"The median Cmax, AUC0-inf, and t1/2 of treprostinil were 680 pg/mL, 3240 hours pg/mL, and 2.35 hours, respectively, in ESRD subjects dosed after dialysis and were 551 pg/mL, 3152 hours pg/mL, and 2.05 hours, respectively, in ESRD subjects dosed before dialysis.",Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23188123/),h,2.35,208969,DB01240,Epoprostenol
,23188123,t1/2,"The median Cmax, AUC0-inf, and t1/2 of treprostinil were 680 pg/mL, 3240 hours pg/mL, and 2.35 hours, respectively, in ESRD subjects dosed after dialysis and were 551 pg/mL, 3152 hours pg/mL, and 2.05 hours, respectively, in ESRD subjects dosed before dialysis.",Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23188123/),h,2.05,208970,DB01240,Epoprostenol
,17545310,inhibition constant (K(i)),"The inhibition constant (K(i)) of MRE-269 for the human IP receptor was 20 nM; in contrast, the K(i) values for other prostanoid receptors were >2.6 microM.","2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545310/),nM,20,221446,DB01240,Epoprostenol
>,17545310,K(i),"The inhibition constant (K(i)) of MRE-269 for the human IP receptor was 20 nM; in contrast, the K(i) values for other prostanoid receptors were >2.6 microM.","2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545310/),μM,2.6,221447,DB01240,Epoprostenol
,17545310,plasma elimination half-life,"Moreover, a microdose pharmacokinetic study in which NS-304 was orally administered to healthy male volunteers showed conversion of NS-304 to MRE-269 and a long plasma elimination half-life for MRE-269 (7.9 h).","2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545310/),h,7.9,221448,DB01240,Epoprostenol
,33545364,bioavailability,We conducted comparative bioavailability analyses of treprostinil exposure from LIQ861 (79.5 μg capsule [approximate delivered dose of 58.1 μg treprostinil]) compared with Tyvaso® (9 breaths [approximate delivered dose of 54 μg treprostinil]).,Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33545364/),μg,79.5,224031,DB01240,Epoprostenol
,33545364,bioavailability,We conducted comparative bioavailability analyses of treprostinil exposure from LIQ861 (79.5 μg capsule [approximate delivered dose of 58.1 μg treprostinil]) compared with Tyvaso® (9 breaths [approximate delivered dose of 54 μg treprostinil]).,Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33545364/),breaths,9,224032,DB01240,Epoprostenol
,8225681,half-lives,"At the end of the infusion, plasma levels of 191 +/- 76 (mean +/- SD) and 645 +/- 191 pg/ml were reached, declining rapidly with half-lives of 6.7 +/- 3.0 and 5.5 +/- 0.84 minutes at the lower and higher infusion rates, respectively.","Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225681/),min,6.7,224243,DB01240,Epoprostenol
,8225681,half-lives,"At the end of the infusion, plasma levels of 191 +/- 76 (mean +/- SD) and 645 +/- 191 pg/ml were reached, declining rapidly with half-lives of 6.7 +/- 3.0 and 5.5 +/- 0.84 minutes at the lower and higher infusion rates, respectively.","Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225681/),min,5.5,224244,DB01240,Epoprostenol
,8225681,area under the plasma concentration-time curve,The area under the plasma concentration-time curve extrapolated to infinity increased with the dose as follows: 28.7 +/- 9.8 and 80.9 +/- 24.8 ng.min/ml.,"Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225681/),[min·ng] / [ml],28.7,224245,DB01240,Epoprostenol
,8225681,area under the plasma concentration-time curve,The area under the plasma concentration-time curve extrapolated to infinity increased with the dose as follows: 28.7 +/- 9.8 and 80.9 +/- 24.8 ng.min/ml.,"Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8225681/),[min·ng] / [ml],80.9,224246,DB01240,Epoprostenol
,6201926,bioavailability,The bioavailability was estimated as about 10% of the dose.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the beagle dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6201926/),%,10,226715,DB01240,Epoprostenol
,6201926,half-lives,"The concentration of radio-labelled compounds in the plasma declined in three phases with half-lives of 3 min, 46 min and approx.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6201926/),min,3,226716,DB01240,Epoprostenol
,6201926,half-lives,"The concentration of radio-labelled compounds in the plasma declined in three phases with half-lives of 3 min, 46 min and approx.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6201926/),min,46,226717,DB01240,Epoprostenol
,6201926,half-life,The half-life of the unchanged drug was 14 min.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the beagle dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6201926/),min,14,226718,DB01240,Epoprostenol
,17951119,m/z,"The mass transitions m/z 397>269 and m/z 356>312 were used to measure beraprost and internal standard, respectively.",Determination of beraprost in human plasma by a high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951119/),,39,238947,DB01240,Epoprostenol
,17951119,m/z,"The mass transitions m/z 397>269 and m/z 356>312 were used to measure beraprost and internal standard, respectively.",Determination of beraprost in human plasma by a high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951119/),,269,238948,DB01240,Epoprostenol
,17951119,m/z,"The mass transitions m/z 397>269 and m/z 356>312 were used to measure beraprost and internal standard, respectively.",Determination of beraprost in human plasma by a high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17951119/),,312,238949,DB01240,Epoprostenol
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.24,241866,DB01240,Epoprostenol
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0. 29,241867,DB01240,Epoprostenol
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.08,241868,DB01240,Epoprostenol
,11133092,IC50,It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 microM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.,A novel pyridazinone derivative as a nonprostanoid PGI2 agonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11133092/),μM,0.081,242724,DB01240,Epoprostenol
,11133092,oral bioavailability,It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 microM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.,A novel pyridazinone derivative as a nonprostanoid PGI2 agonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11133092/),%,56,242725,DB01240,Epoprostenol
,11133092,half-life,It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 microM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.,A novel pyridazinone derivative as a nonprostanoid PGI2 agonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11133092/),h,4.3,242726,DB01240,Epoprostenol
,25277144,terminal half-life,"At the highest dose level, the geometric mean terminal half-life of selexipag and ACT-333679 was 1.4 and 8.7 h, respectively.","Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25277144/),h,1.4,249218,DB01240,Epoprostenol
,25277144,terminal half-life,"At the highest dose level, the geometric mean terminal half-life of selexipag and ACT-333679 was 1.4 and 8.7 h, respectively.","Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25277144/),h,8.7,249219,DB01240,Epoprostenol
,23597147,maximum plasma concentration (Cmax),"Peak concentrations (mean maximum plasma concentration (Cmax) = 1,176 and 2,107 pg/mL) occurred approximately 3.6 hours after dose administration, and overall exposure (under the plasma concentration-time curve from time 0 to 12 hours post dose (AUC0-12) = 7,187 and 12,992 hr*pg/mL) was linear between the 2 mg and 4 mg doses.",Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23597147/),[pg] / [ml],"1,176",266383,DB01240,Epoprostenol
,23597147,maximum plasma concentration (Cmax),"Peak concentrations (mean maximum plasma concentration (Cmax) = 1,176 and 2,107 pg/mL) occurred approximately 3.6 hours after dose administration, and overall exposure (under the plasma concentration-time curve from time 0 to 12 hours post dose (AUC0-12) = 7,187 and 12,992 hr*pg/mL) was linear between the 2 mg and 4 mg doses.",Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23597147/),[pg] / [ml],"2,107",266384,DB01240,Epoprostenol
,23597147,under the plasma concentration-time curve from time 0 to 12 hours post dose (AUC0-12),"Peak concentrations (mean maximum plasma concentration (Cmax) = 1,176 and 2,107 pg/mL) occurred approximately 3.6 hours after dose administration, and overall exposure (under the plasma concentration-time curve from time 0 to 12 hours post dose (AUC0-12) = 7,187 and 12,992 hr*pg/mL) was linear between the 2 mg and 4 mg doses.",Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23597147/),[h·pg] / [ml],"7,187",266385,DB01240,Epoprostenol
,23597147,under the plasma concentration-time curve from time 0 to 12 hours post dose (AUC0-12),"Peak concentrations (mean maximum plasma concentration (Cmax) = 1,176 and 2,107 pg/mL) occurred approximately 3.6 hours after dose administration, and overall exposure (under the plasma concentration-time curve from time 0 to 12 hours post dose (AUC0-12) = 7,187 and 12,992 hr*pg/mL) was linear between the 2 mg and 4 mg doses.",Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23597147/),[h·pg] / [ml],"12,992",266386,DB01240,Epoprostenol
,3538205,half-lives,"After i.v. treatment, drug disposition in the plasma exhibited half-lives of 0.14 h and 4.3 h in rat and 0.07 h, 0.4 h and 2.5 h in monkey.","Studies on the pharmacokinetics of ZK 96 480, a novel PGI2-mimetic, in rat and cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538205/),h,0.14,270714,DB01240,Epoprostenol
,3538205,half-lives,"After i.v. treatment, drug disposition in the plasma exhibited half-lives of 0.14 h and 4.3 h in rat and 0.07 h, 0.4 h and 2.5 h in monkey.","Studies on the pharmacokinetics of ZK 96 480, a novel PGI2-mimetic, in rat and cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538205/),h,4.3,270715,DB01240,Epoprostenol
,3538205,half-lives,"After i.v. treatment, drug disposition in the plasma exhibited half-lives of 0.14 h and 4.3 h in rat and 0.07 h, 0.4 h and 2.5 h in monkey.","Studies on the pharmacokinetics of ZK 96 480, a novel PGI2-mimetic, in rat and cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538205/),h,0.07,270716,DB01240,Epoprostenol
,3538205,half-lives,"After i.v. treatment, drug disposition in the plasma exhibited half-lives of 0.14 h and 4.3 h in rat and 0.07 h, 0.4 h and 2.5 h in monkey.","Studies on the pharmacokinetics of ZK 96 480, a novel PGI2-mimetic, in rat and cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538205/),h,0.4,270717,DB01240,Epoprostenol
,3538205,half-lives,"After i.v. treatment, drug disposition in the plasma exhibited half-lives of 0.14 h and 4.3 h in rat and 0.07 h, 0.4 h and 2.5 h in monkey.","Studies on the pharmacokinetics of ZK 96 480, a novel PGI2-mimetic, in rat and cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538205/),h,2.5,270718,DB01240,Epoprostenol
,3538205,Total clearance,Total clearance was 14 ml/min/kg in the latter species.,"Studies on the pharmacokinetics of ZK 96 480, a novel PGI2-mimetic, in rat and cynomolgus monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538205/),[ml] / [kg·min],14,270719,DB01240,Epoprostenol
,24603117,Cmax,"The mean (% CVb) Cmax was 0.538 (37%), 0.714 (51%), and 0.559 (45%) ng/mL on days 1, 7, and 8, respectively.",Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),[ng] / [ml],0.538,273759,DB01240,Epoprostenol
,24603117,Cmax,"The mean (% CVb) Cmax was 0.538 (37%), 0.714 (51%), and 0.559 (45%) ng/mL on days 1, 7, and 8, respectively.",Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),[ng] / [ml],0.714,273760,DB01240,Epoprostenol
,24603117,Cmax,"The mean (% CVb) Cmax was 0.538 (37%), 0.714 (51%), and 0.559 (45%) ng/mL on days 1, 7, and 8, respectively.",Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),[ng] / [ml],0.559,273761,DB01240,Epoprostenol
,24603117,AUC0-24,"After a single dose on day 1 (first dose) and day 8 (last dose), mean (CVb%) AUC0-24 was 2.45 (26%) and 2.96 (28%) h·ng·mL, respectively.",Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),h·ml·ng,2.45,273762,DB01240,Epoprostenol
,24603117,AUC0-24,"After a single dose on day 1 (first dose) and day 8 (last dose), mean (CVb%) AUC0-24 was 2.45 (26%) and 2.96 (28%) h·ng·mL, respectively.",Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),h·ml·ng,2.96,273763,DB01240,Epoprostenol
,24603117,steady-state AUC0-24,"The mean (% CVb) steady-state AUC0-24 after TID regimen (on day 7) was 6.53 (34%) h·ng·mL, which was not significantly different from mean AUC0-∞ (7.39 h·ng·mL) on day 1 adjusted for 3 doses.",Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),h·ml·ng,6.53,273764,DB01240,Epoprostenol
,24603117,AUC0-∞,"The mean (% CVb) steady-state AUC0-24 after TID regimen (on day 7) was 6.53 (34%) h·ng·mL, which was not significantly different from mean AUC0-∞ (7.39 h·ng·mL) on day 1 adjusted for 3 doses.",Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),h·ml·ng,7.39,273765,DB01240,Epoprostenol
,24603117,apparent t1/2,"Mean apparent t1/2 was similar on days 1, 7, and 8 (1.1-1.4 hours).",Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),h,1.1-1.4,273766,DB01240,Epoprostenol
,24603117,Trough concentrations,Trough concentrations of treprostinil were comparable across study days ranging from 0.046 to 0.053 ng/mL before the AM dose and from 0.27 to 0.39 ng/mL before the evening dose.,Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),[ng] / [ml],0.046 to 0.053,273767,DB01240,Epoprostenol
,24603117,Trough concentrations,Trough concentrations of treprostinil were comparable across study days ranging from 0.046 to 0.053 ng/mL before the AM dose and from 0.27 to 0.39 ng/mL before the evening dose.,Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24603117/),[ng] / [ml],0.27 to 0.39,273768,DB01240,Epoprostenol
